Efficacy of Degu Aspart Dual Insulin in the Treatment of Type 2 Diabetes Mellitus Poorly Controlled by Oral Antidiabetic Agents
Objective To analyze the effect of insulin degludec/insulin aspart(IDegAsp)on type 2 diabetes mellitus poorly controlled by oral antidiabetic agents(OADS).Methods Ninety-two patients with type 2 diabetes with poorly controlled OADS treated in Zhangqiu District Hospital of Traditional Chinese Medicine of Jinan City from August 2022 to July 2023 were selected as the study objects,and they were divided into two groups with 46 cases each ac-cording to random number table method.The control group was treated with insulin glargine,and the study group was treated with IDegAsp.Blood glucose level,blood glucose fluctuation value and incidence of hypoglycemia were com-pared between the two groups.Results After 3 months of treatment,the glycosylated hemoglobin,2 h postprandial blood glucose and fasting blood glucose in the study group were lower than those in the control group,and the differ-ences were statistically significant(all P<0.05).The blood glucose standard deviation,24 h average blood glucose value and postprandial blood glucose fluctuation value of the study group were lower than those of the control group,and the differences were statistically significant(all P<0.05).The blood glucose standard time of the study group(6.15±1.52)d was shorter than that of the control group(7.89±1.60)d,and the difference was statistically significant(t=5.347,P<0.05).There was no significant statistically difference in the incidence of hypoglycemia between the two groups(P>0.05).Conclusion IDegAsp can effectively improve the blood glucose value of type 2 diabetes patients with poorly controlled OADS,inhibit their blood glucose fluctuations,and does not increase the risk of hypoglycemia.
万方数据
维普
